Perioperative screening, management, and surveillance of Barrett's esophagus in bariatric surgical patients

Geraldine J Ooi¹, Alison Browning², Michael W Hii,^{2,3} and Matthew Read^{2,3}

¹Department of Surgery, Central Clinical School, Monash University, Prahran, Australia

²Department of Upper GI and Hepatobiliary Surgery, St. Vincent's Hospital, Fitzroy, Australia

³Department of Surgery, the University of Melbourne, St. Vincent's Hospital, Fitzroy, Australia

Address for correspondence: Geraldine Ooi, Department of Surgery, Central Clinical School, Monash University, Level 6, 99 Commercial Road, Prahran, Victoria 3181, Australia.
geraldineooi@gmail.com

Short title: Barrett's Esophagus and Bariatric Surgery

Abstract

Obesity is a strong risk factor for Barrett's esophagus (BE), the only proven precursor lesion to EAC. Bariatric surgery is currently the only reliable treatment that achieves of long-term sustained weight loss, however, it can markedly affect the development of *de novo* BE, and the progression or regression of existing BE. Bariatric procedures may also have implications on future surgical management of any consequent EAC. In this review, we examine current evidence and published guidelines for BE in bariatric surgery. Current screening practices before bariatric surgery vary substantially, with conflicting recommendations from bariatric societies. If diagnosed, the presence of BE may alter the type of bariatric procedure. A selective screening approach prevents unnecessary endoscopy, however, there is poor symptom correlation with disease. Studies suggest that sleeve gastrectomy predisposes patients to gastroesophageal reflux and *de novo* BE. Conversely, Roux-en-Y gastric bypass is associated with decreased reflux and potential improvement or resolution of BE. There are currently no guidelines addressing surveillance for BE following bariatric surgery.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/nyas.14441](https://doi.org/10.1111/nyas.14441).

BE is an important consideration in the management of bariatric surgical patients. Evidence-based recommendations are required to guide procedure selection and postoperative surveillance.

Keywords: Barrett's esophagus; bariatric surgery; endoscopy; esophagus; stomach

Introduction

Worldwide rates of obesity have tripled over the last few decades, with over 13% of the adult population now classified as obese (body mass index (BMI) over 30kg/m²).¹ Bariatric surgery is currently the only reliable means of achieving substantial and sustained weight loss accompanied by remission and reduced incidence of metabolic comorbidities in morbidly obese individuals^{2,3}.

Esophageal pathology is relatively common in obesity,^{4,5} and potentially exacerbated by bariatric surgical procedures. This includes Barrett's esophagus (BE), the only known precursor lesion of esophageal adenocarcinoma (EAC). There are multiple mechanisms, both mechanical and metabolic, for this association in obesity. The incidence of EAC in Western society has increased up to five-fold in the last few decades,⁶ closely mirroring the rising rates of obesity.

It is important to recognize BE in the bariatric surgical population. Preoperative endoscopy may be an opportune time to screen an already at-risk population, and its detection can suggest a change of surgical strategy. Second, bariatric surgical procedures can impact gastroesophageal reflux (GER) and, therefore, theoretically affect the development of *de novo* BE, or progression and regression of existing BE. Finally, bariatric surgery can significantly impact future curative treatments for esophageal adenocarcinoma (EC) that may develop from BE.

In this review, we discuss the link between BE, obesity, and bariatric surgery, and review the evidence around perioperative screening and surveillance.

BE and obesity

BE is a premalignant condition characterized by the conversion of the normal esophageal squamous epithelium to the metaplastic columnar epithelium containing goblet cells.⁷ This is thought to be in response to prolonged exposure to acid reflux. BE can progress from metaplasia to dysplasia, and subsequently EAC.

Central adiposity and high BMI are risk factors for BE. A meta-analysis by Singh *et al.* showed a significant increase in odds of BE with central adiposity (OR = 1.98; 95% CI: 1.52–2.57), with a strong dose–response relationship.⁸ This association remains significant after controlling for gastroesophageal reflux disease (GERD). Higher BMI is also significantly correlated with increased length of BE ($r = 0.25$, $P < 0.0001$) and greater rates of long-segment BE.⁹

Various mechanisms have been implicated in the development of BE in obesity. These can be divided into mechanical, metabolic, and dietary factors.⁵

Mechanically, obesity increases intragastric pressures and disrupts the antireflux mechanisms, both of which encourage acid reflux into the esophagus. High BMI and waist circumference are independently associated with dysfunction of the GE function, including separation of the diaphragmatic hiatus and increased frequency of lower esophageal sphincter relaxation,^{10,11} allowing passage of the refluxate into the esophagus. Intragastric pressures from visceral abdominal fat further exacerbate acid reflux.¹²

Metabolic factors are also important mechanisms in the development of BE and neoplasia. Overexpansion of adipose tissue in obesity produces a state of low-grade systemic inflammation, owing to changes in immune profile to a proinflammatory state and over-expression of inflammatory cytokines, such as tumor necrosis factor- α , interleukin (IL)-1 β , and IL-6.¹³ The paracrine and endocrine profile of adipose tissue changes with increased leptin and decreased adiponectin. Increasing lipolysis results in the release of saturated free fatty acids, and excess adiposity results in ectopic fat storage in depots, such as the liver, pancreas, and muscle, leading to organ dysfunction and insulin resistance.¹⁴ These changes in leptin, adiponectin, insulin resistance, and systemic inflammation have all been linked to the development and progression of BE.⁵

Various dietary factors have been associated with the development of BE, many of which are associated with obesity. Meta-analyses show that low dietary fiber intake is associated with an increased risk of BE and EAC.¹⁵ Composition of dietary fats, towards high animal fat intake, has been shown to change bile acid composition and increase rates of metaplasia, dysplasia, and adenocarcinoma (AC) in animal models.¹⁶ Alternatively, a high intake of beta-carotene (for example, from carrots, dark leafy greens, and cantaloupe) is protective from dysplastic BE.¹⁷

Bariatric surgery and reflux disease

GERD refers to pathological, retrograde passage of gastric and/or biliopancreatic contents into the esophagus, such that symptoms or pathology occurs.¹⁸ In the general population, it is one of the most common diagnoses during endoscopy, with a prevalence of between 10 and 20%. This prevalence increases with obesity and may be up to 60%.¹⁹

Trends in bariatric surgery have changed dramatically over the last 10–20 years. In this time, sleeve gastrectomy (SG) has increased from 3.0% in 2008 to 54% of all cases performed in the United States in 2014. Laparoscopic adjustable gastric banding (LAGB) has fallen from 29% to 1% of bariatric cases, and Roux-en-Y gastric bypass (RYGB) decreased from 52% to 32%.²⁰ Randomized control trials have shown similar weight loss outcomes for SG and RYGB.^{21,22} These trends are likely due to a combination of reasons, such as procedural complexity, insurance coverage, complication profile, and surgeon/patient preferences.

Bariatric surgery can have profound effects on the mechanisms promoting or alleviating GERD. RYGB is a popular choice for obese patients with significant reflux, with studies consistently showing symptomatic relief, reduction in acid suppressor medication, improvement in acid exposure, and

esophagitis.²³ Mechanistically, RYGB creates a small low-pressure gastric pouch with few acid-producing parietal cells and a long Roux limb that prevents reflux of duodenal contents into the esophagus. Prevention of bile reflux is important, given the link between BE and the exposure of the esophageal mucosa to the biliopancreatic fluid.²⁴ Studies on LAGB have conflicting results, with both symptomatic relief and reduction in medication, as well as studies reporting exacerbation of reflux.²³

The majority of studies that have assessed reflux after SG report an increase in GERD symptoms and objective evidence of acid reflux, such as erosive esophagitis.²⁵ Proposed mechanisms that exacerbate reflux include an increase in intragastric pressures, intrathoracic sleeve migration, fundal dilatation, delayed gastric emptying, and esophageal motility disorders.²³ However, there are some studies that have shown the opposite, with improvement in GERD and the esophagitis.^{26–28} This could be due to faster gastric emptying, alterations in the gastrointestinal (GI) hormonal milieu, decreased acid secretion, and postoperative weight loss. Technical factors, such as concomitant hiatus hernia repair, may also contribute to differences between studies.

With the link between obesity, BE and EAC well established, diagnosing BE in bariatric surgical patients is important. Understanding the effect of bariatric procedures on BE is vital for tailoring surgery to individuals and counseling patients on the risk. The presence of BE in patients undergoing bariatric surgery is particularly important, as bariatric procedures can significantly influence surgical options for curative management of EAC.

The primary aim of this review was to summarize the current evidence on:

1. Screening for BE before bariatric surgery;
2. The effects of bariatric surgery on BE;
3. Surveillance for patients who have/develop BE following bariatric surgery.

Literature search

We performed a comprehensive literature search to identify studies reporting any experiences or outcomes with BE and bariatric surgery. We searched MEDLINE, PubMed, and the Cochrane Library (until January 2020). The search items used were derivatives of BE and bariatric surgery. Original research, clinical trials, review articles, and meta-analyses were all included.

Screening for BE before bariatric surgery

The role of routine endoscopy before bariatric surgery remains controversial. There is a wide variety of practices, with many centers performing routine endoscopy while others practice selective endoscopy, often based on symptoms.²⁹ This is reflected by varying recommendations among surgical societies (Table 1). The European Association for Endoscopic Surgery (EAES) recommends routine upper GI (UGI) endoscopy or upper GI series for all bariatric patients.³⁰ By contrast, the American Society for Metabolic and Bariatric Surgery (ASMBS) and the American Society for Gastrointestinal Endoscopy (ASGE) both suggest an individualized approach, with investigations performed for those with clinically significant symptoms.^{31,32} The evidence underlying these recommendations are somewhat weak.

Advocates of selective endoscopy argue that clinically important findings are not common in the bariatric population, and therefore endoscopy can be offered based on the symptoms and the risk. Current reports suggest that the proportion of patients where endoscopy alters surgical approach or has a clinical impact varies from <1% to 24.6% of patients.^{33–37} There is significant heterogeneity between studies around the definition of “clinically significant” impact, with some defining this as change or delay in surgery, while others include the change in medical management as significant.

Many studies have reported a lack of correlation between symptoms and detection of BE (Table 2).^{36,38–41} Up to 60% of patients diagnosed with BE on preoperative endoscopy are asymptomatic. Saarinen *et al.*³⁶ examined the endoscopy results of 1275 bariatric patients, and reported a rate of BE of 3.7% ($n = 47$), of whom 28 (59.6%) were asymptomatic. Similarly, D’Silva *et al.*⁴¹ studied 675 preoperative endoscopies and found that 60% of those findings consistent with GERD, including BE and reflux esophagitis, were asymptomatic. The lack of symptoms together with the lack of accurate noninvasive tests is likely to decrease the efficacy of a selective approach to endoscopy before bariatric surgery.

Endoscopy has the advantage of detecting mucosal lesions, such as BE or early AC, which are often imperceptible or too subtle to be diagnosed by other means. In individual studies, BE was found in <1% to 15% of preoperative endoscopy (Table 2).^{36,37,39–48} Two systematic reviews and meta-analyses have examined the utility of preoperative endoscopy.^{38,49} Parikh *et al.* reported an overall incidence of BE of 1% (45 of 4511 patients), with EAC found in 0.9% (4 of 4511). Bennett *et al.* combined the findings of 19 studies with 5802 patients, finding an incidence of BE of 2.1% and esophageal cancer in 0.2%. Data on how many patients were symptomatic is lacking, as only two studies in the meta-analysis made the distinction between those with and without symptoms. Both these systematic reviews have advocated for selective endoscopy based on relatively low numbers.

Given the number of bariatric operations performed annually worldwide, and the implications for BE screening and early cancer detection, over 2% of bariatric patients with BE is a clinically significant number. The clinical significance is further increased given that majority of bariatric patients are relatively young, which leads to an increased lifelong risk of cancer.

Additionally, bariatric surgery has implications for curative surgical procedures and conduit reconstruction. Resectional procedures, such as SG or resectional RYGB, eliminate the use of the stomach as a future reconstructive option during esophageal resection procedures. Reconstruction with other conduits, such as colon or small bowel, are technically more demanding and have an increased risk.⁵⁰ Additionally, any gastric procedure may cause scarring or stricturing, increasing the chance of complications if future surgery is required.⁵¹ In this regard, excluding preexisting BE is vital before committing to bariatric surgery.

Effect of bariatric surgery on BE

SG

Current published literature studying BE in SG patients strongly suggests an increased rate of *de novo* BE after SG. A recent systematic review by Yeung *et al.* (2020) reported on the impact of SG on

reflux-related measures, including symptomatic reflux, erosive esophagitis, and BE²⁵ (Table 3). Five studies examined the incidence of BE after SG. Over a follow-up period of 24 months or more, the rate of *de novo* BE was 8% (95% CI: 4–13%, $P < 0.0001$). This review showed significant increases in *de novo* reflux (rate of 20%), erosive esophagitis (28%), and PPI use (36%). Furthermore, 4% of patients underwent conversion to RYGB for the treatment of severe reflux. All studies were retrospective or cohort studies with no randomized control trials, and there was a large amount of heterogeneity in all analyses.

Table 4 shows a summary of recent individual studies examining the incidence of BE after SG. Participant numbers range from 43 to 231 and a follow-up varied from 58 months to over 10 years. Rates of *de novo* BE ranged from 1.2% up to 18.8%, with between 5 to 10 years of a follow-up.

Roux-en-Y gastric bypass

RYGB appears to be beneficial in the setting of BE. A systematic review by Adil *et al.* in 2019 reported on 117 patients with biopsy-proven preoperative BE and endoscopic follow-up at over 1 year after RYGB surgery. Meta-analysis showed significant regression in BE after RYGB, with a risk difference of -0.56 (95% CI: -0.69 to -0.43, $P < 0.001$). This corresponded to 64 participants (54.7%) showing histological regression, with two (1.7%) showing progression. This effect was seen in both short- and long-segment BE (risk difference of -0.51 and -0.46, respectively, $P < 0.001$ for both).^{52,53} Heterogeneity between studies was moderate, with some publication bias owing to a small study size (Table 3).

Results of individual studies are seen in Table 5. All studies report improvement in BE after RYGB. Felsenreich *et al.* studied 10 patients who underwent RYGB as a revisional procedure for SG after a diagnosis of BE. They reported 80% remission, and objective improvements in acid exposure (36.8% to 2.8% after a 24-h acid exposure) and DeMeester score (100 to 16.3). Individual studies suggest better rates of resolution in short- versus long-segment BE^{52,53}. The effects of weight loss quantity on the resolution of BE has not previously been studied, but evidence suggests that greater weight loss may contribute to the resolution of BE.⁹ These studies further support the role of RYGB as a combined bariatric and antireflux procedure.

Many have advocated for RYGB as a revision procedure for patients who experience significant GERD post-SG. Felsenreich *et al.* (2019) studied 10 patients who underwent RYGB after SG due to severe reflux and BE.⁵⁴ At a mean follow-up time of 33.4 months, they noted a significant decrease in acid exposure (36.8% to 3.8% 24-h acid exposure) and drop in DeMeester score (100 to 16.3). Furthermore, BE resolved in eight patients, including in one patient with small areas of dysplasia on preoperative endoscopy.

Other procedures

Few studies have examined the effect of other bariatric procedures on BE. There is only one case report of BE,⁵⁵ and reports within larger outcomes studies of BE observed^{56,57} after LAGB. Due to paucity in the literature, the specific incidence of BE after gastric banding is not known.

We could not find studies specifically addressing the incidence of BE after other procedures, including single anastomosis gastric bypass, single anastomosis duodenal bypass, or biliopancreatic diversion.

Surveillance for *de novo* BE after bariatric surgery

There are currently no society guidelines specifically addressing potential *de novo* BE and surveillance postbariatric surgery. Current guidelines focus on known risk factors for BE, including chronic GERD, older age, male gender, central obesity, Caucasian race, and tobacco use.⁵⁹

The Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery encourage “regular lifelong qualified surveillance” for all patients after bariatric procedures, including clinical, metabolic, and nutritional assessment. In particular, persistent severe GI symptoms should be followed up with endoscopy and/or CT as a first diagnostic option.⁶⁰ Similarly, the American Society of Gastrointestinal Endoscopy (ASGE) recommends endoscopy as the first-line diagnostic study for bariatric patients with abdominal pain, nausea, or vomiting.³² These recommendations prevent unnecessary delay in the diagnosis of significant pathology due to erroneously attributing them to a normal postoperative course after a bariatric procedure. The emphasis on symptoms, however, is likely to miss most cases of BE. No routine endoscopic follow-up schedule has been recommended by any society.

There is no consensus on screening and surveillance for BE in the general population, and little evidence to support its use. Most societies have used a cut-off prevalence of BE of 10% to recommend screening^{61,62}. Several risk factors have been identified, including the history of GERD, male gender, white race, age >50 years, smoking, obesity, and family history. The American Society of Gastrointestinal Endoscopy (ASGE) recognizes high-, moderate-, and low-risk groups. High-risk populations include those with a family history of EAC or BE, where screening is recommended. The moderate-risk group includes patients with GERD and another additional risk factor, including age >50, obesity/central adiposity, history of smoking, or male gender. The screening was not recommended for low-risk populations. When applied to the bariatric population, those with symptoms of GERD will be of “moderate-risk” and, therefore, warrant screening and surveillance.

One concerning feature of acid reflux and BE after SG is the lack of correlation between endoscopic findings and reported symptoms.^{25,63,64} Soricelli *et al.* studied the association between symptoms of GER and endoscopic esophageal lesions after SG in 249 patients over a mean follow-up of 66 months.⁶⁴ They found no significant correlation between the symptoms of GERD and the severity of esophagitis or the presence of BE. In a study on GERD after SG, Genco *et al.* reported highest symptomatic reflux scores for Grade A and B esophagitis (visual analogue scale (VAS) of 3.1–3.4), lower reflux scores for Grade C and D esophagitis (VAS = 2.4–2.8), and the lowest reflux scores in patients found to have BE (VAS = 1.3).⁶³ These studies highlight the difficulties in triaging patients with post-SG for selective gastroscopy.

Given current evidence suggesting the development of reflux and *de novo* BE in sleeve patients, it may be prudent to advocate for surveillance of patients 5–10 years after SG, or sooner if they are symptomatic.

Summary

Preoperative screening

GERD and BE are often asymptomatic. Given the implications of some bariatric procedures on the development of reflux and BE and also on future cancer treatment, endoscopy plays a vital role in preoperative assessment. Other modalities, such as UGI series, are of little utility for the detection of GERD or mucosal abnormality. If significant pathology, such as esophagitis or BE is found, the patient and surgeon should strongly consider RYGB over other procedures.

Effect of bariatric surgery

Current evidence indicates that SG predisposes to *de novo* GERD and BE. On the other hand, RYGB is associated with resolution or reduction in length of BE, as well as reduced GERD. Therefore, RYGB is ideal for those with preoperative BE or GERD. Unless there is a specific indication for resection, the bypassed stomach should be left *in situ*, as it may be used as a conduit if an esophagectomy is required in the future.

Postoperative surveillances

Routine postoperative surveillance should strongly be considered in all patients, particularly those with SG. Reliance on symptomatology to select patients for surveillance may be unreliable and could result in missed disease.

Conclusion

BE is an important consideration in patients undergoing bariatric surgery. Development and progression of BE is intrinsically linked with obesity, and the level of adiposity correlates with the risk. Bariatric procedures can influence the progression of BE, and can also impact future cancer surgery. Current evidence suggests BE is more likely to develop or progress after SG, while reports have shown regression and resolution after RYGB. Screening before bariatric surgery may be valuable as, theoretically, it helps guide procedure selection and may inform future BE surveillance. Strong consideration should be given to endoscopic surveillance after SG, given the reported rates of development of BE at 5–10 years. Further prospective studies are required to strengthen these conclusions and facilitate the development of evidence-based guidelines for perioperative management of BE in bariatric patients.

References

1. Obesity and overweight. World Health Organisation, 2020. (Accessed 28 March 2020, 2020, at <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>.)
2. Gloy VL, Briel M, Bhatt DL, *et al.*. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. *BMJ* 2013;347:5934.
3. Jakobsen GS, Småstuen MC, Sandbu R, *et al.*. Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities. *JAMA* 2018;319.
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *The Lancet* 2008;371:569-78.
5. Chandar AK, Iyer PG. Role of Obesity in the Pathogenesis and Progression of Barrett's Esophagus. *Gastroenterology Clinics of North America* 2015;44:249-64.
6. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. *Ann Oncol* 2012;23:3155-62.
7. Whiteman DC, Kendall BJ. Barrett's oesophagus: epidemiology, diagnosis and clinical management. *Med J Aust* 2016;205:317-24.
8. Singh S, Sharma AN, Murad MH, *al e.* Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2013;11:1407.
9. Abdallah J, Maradey-Romero C, Lewis S, Perzynski A, Fass R. The relationship between length of Barrett's oesophagus mucosa and body mass index. *Aliment Pharmacol Ther* 2014;41:137-44.
10. Derakhshan MH, Robertson EV, Fletcher J, *al e.* Mechanisms of association between BMI and dysfunction of the gastro-oesophageal barrier in patients with normal endoscopy. *Gut* 2012;61:337-43.
11. Wu JC, Mui LM, Cheung CM, *al e.* Obesity is associated with increased transient lower esophageal sphincter relaxation. *Gastroenterology* 2007;132:883-9.
12. Pandolfino JE, El-Serag HB, Zhang Q, *al e.* Obesity: a challenge to esophagogastric junction integrity. *Gastroenterology* 2006;130:639-49.
13. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. *Cell* 2014;156:20-44.
14. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. *N Engl J Med* 2014;371:1131-41.
15. Sun L, Zhang Z, Xu J, Xu G, Liu X. Dietary fiber intake reduces risk of Barrett's esophagus and esophageal cancer. *Critical Reviews in Food Science and Nutrition* 2017;57:2749-57.
16. Chen K-, Mukaisho K-I, Sugihara H, Araki Y, Yamamoto G, Hattori T. High animal-fat intake changes the bile-acid composition of bile juices and enhances the development of Barrett's

esophagus and esophageal adenocarcinoma in a rat duodenal-contents reflux model. *Cancer Sci* 2007;98:1683-8.

17. Ibiebele TI, Hughes MC, Nagle CM, Bain CJ, Whiteman DC, Webb PM. Dietary antioxidants and risk of Barrett's esophagus and adenocarcinoma of the esophagus in an Australian population. *Int J Cancer* 2013;133:214-25.
18. Katz PO, Gerson L, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 2013;108:308-28.
19. Dent J, El-Serag HB, Wallander MA, al e. Epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut* 2005;54:710-7.
20. Abraham A, Ikramuddin S, Jahansouz C, Arafat F, Hevelone N, Leslie D. Trends in bariatric surgery: Procedure selection, revisional surgeries, and readmissions. *Obes Surg* 2016;26:1371-7.
21. Kang JH, Le AL. Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials. *Medicine* 2017;96:e8632.
22. Ulas Biter L, Gadiot RPM, Grotenhuis BA, *et al.*. The Sleeve Bypass Trial: a multicentre randomized controlled trial comparing the long term outcomes of laparoscopic sleeve gastrectomy and gastric bypass for morbid obesity in terms of excess BMI loss percentage and quality of life. *BMC Obesity* 2015;2:30.
23. Altieri MS, Pryor AD. Gastroesophageal Reflux Disease After Bariatric Procedures. *Surgical Clinics of North America* 2015;95:579-91.
24. McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. *Aliment Pharmacol Ther* 2011;34:146-65.
25. Yeung KTD, Penney N, Ashrafian L, Darzi A, Ashrafian H. Does sleeve gastrectomy expose the distal esophagus to severe reflux?: A systematic review and meta-analysis. *Annals of Surgery* 2020;271:257-65.
26. Pallati PK, Shaligram A, Shostrom VK, al e. Improvement in gastroesophageal reflux disease symptoms after various bariatric procedures: review of the bariatric outcomes longitudinal database. *Surg Obes Relat Dis* 2014;10:502-7.
27. Rawlins L, Rawlins MP, Brown CC, al e. Sleeve gastrectomy: 5 year outcomes of a single institution. *Surg Obes Relat Dis* 2013;9:21-5.
28. Sharma A, Aggarwal S, Ahuja V, al e. Evaluation of gastroesophageal reflux before and after sleeve gastrectomy using symptom scoring, scintigraphy, and endoscopy. *Surg Obes Relat Dis* 2014;10:600-5.
29. Zanotti D, Elkalaawy M, Hashemi M, Jenkinson A, Adamo M. Current Status of Preoperative Oesophago-Gastro-Duodenoscopy (OGD) in Bariatric NHS Units-a BOMSS Survey. *Obesity Surgery* 2016;26:2257-62.
30. Sauerland S, Angrisani L, Belachew M, *et al.*. Obesity surgery: Evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). *Surgical Endoscopy* 2005;19:200-21.

31. Mechanick JI, Youdim A, Jones DB, *et al.*. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. *Surg Obes Relat Dis* 2013;9:159-91.
32. American Society for Gastrointestinal Endoscopy. The role of endoscopy in the bariatric surgery patient. *Gastrointestinal Endoscopy* 2015;81:1063-72.
33. Zeni TM, Frantzides CT, Mahr C, *et al.*. Value of preoperative upper endoscopy in patients undergoing laparoscopic gastric bypass. *Obesity Surgery* 2006;16:142-6.
34. Mong C, Van Dam J, Morton J, Gerson L, Curet M, Banerjee S. Preoperative endoscopic screening for laparoscopic Roux-en-Y gastric bypass has a low yield for anatomic findings. *Obesity Surgery* 2008;18:1067-73.
35. Korenkov M, Sauerland S, Shah S, *et al.*. Is routine preoperative upper endoscopy in gastric banding patients really necessary? . *Obes Surg* 2006;16:45-7.
36. Saarinen T, Kettunen U, Pietilainen KH, Juuti A. Is preoperative gastroscopy necessary before sleeve gastrectomy and Roux-en-Y gastric bypass? *Surgery for Obesity and Related Diseases* 2018;14:757-62.
37. Schigt A, Coblijn U, Lagarde S, Kuiken S, Scholten P, Van Wagensveld B. Is esophagogastroduodenoscopy before Roux-en-Y gastric bypass or sleeve gastrectomy mandatory? *Surgery for Obesity and Related Diseases* 2014;10:411-7.
38. Bennett S, Gostimir M, Shorr R, Mallick R, Mamazza J, Neville A. The role of routine preoperative upper endoscopy in bariatric surgery: a systematic review and meta-analysis. *Surg* 2016;12:1116-25.
39. Azagury D, Dumonceau JM, Morel P, Chassot G, Huber O. Preoperative work-up in asymptomatic patients undergoing Roux-en-Y gastric bypass: Is endoscopy mandatory? *Obesity Surgery* 2006;16:1304-11.
40. Humphreys LM, Meredith H, Morgan J, Norton S. Detection of asymptomatic adenocarcinoma at endoscopy prior to gastric banding justifies routine endoscopy. *Obes Surg* 2012;22:594-6.
41. D'Silva M, Bhasker AG, Kantharia NS, Lakdawala M. High-Percentage Pathological Findings in Obese Patients Suggest that Esophago-gastro-duodenoscopy Should Be Made Mandatory Prior to Bariatric Surgery. *Obesity Surgery* 2018;28:2753-9.
42. Abou Hussein B, Khammas A, Shokr M, *et al.*. Role of routine upper endoscopy before bariatric surgery in the Middle East population: A review of 1278 patients. *Endoscopy International Open* 2018;6:E1171-E6.
43. D'Hondt M, Steverlynck M, Pottel H, *et al.*. Value of preoperative esophagogastroduodenoscopy in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass. *Acta Chirurgica Belgica* 2013;113:249-53.
44. Moulla Y, Lyros O, Mehdorn M, *et al.*. Preoperative Upper-GI Endoscopy Prior to Bariatric Surgery: Essential or Optional? *Obesity Surgery* 2020.

45. Ozeki KA, Tran SA, Cheung R, Eisenberg D. Preoperative Endoscopic Findings in Veterans Undergoing Bariatric Surgery: Prevalence and Predictors of Barrett's Esophagus. *Obesity Surgery* 2020;30:657-63.
46. Schneider R, Lazaridis I, Kraljevic M, Beglinger C, Wolnerhanssen B, Peterli R. The impact of preoperative investigations on the management of bariatric patients; results of a cohort of more than 1200 cases. *Surgery for Obesity and Related Diseases* 2018;14:693-9.
47. Sharaf RN, Weinshel EH, Bini EJ, Rosenberg J, Sherman A, Ren CJ. Endoscopy plays an important preoperative role in bariatric surgery. *Obesity Surgery* 2004;14:1367-72.
48. Wolter S, Dupree A, Miro J, *et al.* Upper Gastrointestinal Endoscopy prior to Bariatric Surgery-Mandatory or Expendable? An Analysis of 801 Cases. *Obesity Surgery* 2017;27:1938-43.
49. Parikh M, Liu J, Vieira D, *et al.* Preoperative Endoscopy Prior to Bariatric Surgery: a Systematic Review and Meta-Analysis of the Literature. *Obesity Surgery* 2016;26:2961-6.
50. Burton PR, Ooi GJ, Laurie C, *et al.* Diagnosis and Management of Oesophageal Cancer in Bariatric Surgical Patients. *Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract* 2016;20:1683-91.
51. Kuruba R, Jawad M, Karl RC, Murr MM. Technique of resection of esophageal adenocarcinoma after Roux-en-Y gastric bypass and literature review of esophagogastric tumors after bariatric procedures. *Surg* 2009;5:576-81.
52. Adil MT, Al-taan O, Rashid F, *et al.* A Systematic Review and Meta-Analysis of the Effect of Roux-en-Y Gastric Bypass on Barrett's Esophagus. *Obesity Surgery* 2019;29:3712-21.
53. Csendes A, Burgos AM, Smok G, Burdiles P, Henriquez A. Effect of gastric bypass on Barrett's esophagus and intestinal metaplasia of the cardia in patients with morbid obesity. *Journal of Gastrointestinal Surgery* 2006;10:259-64.
54. Signorini F, Viscido G, Bocco MCA, Obeide L, Moser F. Impact of Gastric Bypass on Erosive Esophagitis and Barret's Esophagus. *Obesity Surgery* 2020.
55. Felsenreich DM, Langer FB, Bichler C, *et al.* Roux-en-Y Gastric Bypass as a Treatment for Barrett's Esophagus after Sleeve Gastrectomy. *Obesity Surgery* 2019.
56. Varela JE. Barrett's esophagus: A late complication of laparoscopic adjustable gastric banding. *Obesity Surgery* 2010;20:244-6.
57. Rosenthal RJ, Szomstein S, Kennedy CI, Soto FC, Zundel N. Laparoscopic surgery for morbid obesity: 1,001 Consecutive bariatric operations performed at the Bariatric Institute, Cleveland Clinic Florida. *Obesity Surgery* 2006;16:119-24.
58. Gehwolf P, Kienzl-Wagner K, Cakar-Beck F, Schafer A, Wykypiel H. Laporoscopic adjustable gastric banding: An underestimated risk factor for the development of esophageal cancer? A nationwide survey. *Diseases of the Esophagus* 2018;31 (Supplement 1):195.
59. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and management of Barrett's esophagus. *Am J Gastroenterol* 2016;111:30-50.

60. Fried M, Yumuk V, Oppert J-M, *et al.*. Interdisciplinary European guidelines on metabolic and bariatric surgery. *Obes Facts* 2013;6:449-68.
61. For which populations is screening for BO cost-effective? Cancer Council Australia, 2014. (Accessed 14 May, 2020, at https://wiki.cancer.org.au/australia/Clinical_question:For_which_populations_is_screening_for_BO_cost-effective%3F.)
62. Qumseya BJ, Sultan S, Bain P, *et al.*. ASGE guideline on screening and surveillance of Barrett's esophagus. *Gastrointestinal Endoscopy* 2019;90:335-59.
63. Genco A, Soricelli E, Casella G, *et al.*. Gastroesophageal reflux disease and Barrett's esophagus after laparoscopic sleeve gastrectomy: a possible, underestimated long-term complication. *Surgery for Obesity and Related Diseases* 2017;13:568-74.
64. Soricelli E, Casella G, Baglio G, Maselli R, Ernesti I, Genco A. Lack of correlation between gastroesophageal reflux disease symptoms and esophageal lesions after sleeve gastrectomy. *Surgery for Obesity and Related Diseases* 2018;14:751-6.
65. Bradley DD, Louie BE, Chen J, Aye RW, McMahon R, Farivar AS. The effect of concurrent esophageal pathology on bariatric surgical planning. *Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract* 2015;19:111-5; discussion 5-6.
66. Carabotti M, Avallone M, Cereatti F, *et al.* Usefulness of Upper Gastrointestinal Symptoms as a Driver to Prescribe Gastrosocopy in Obese Patients Candidate to Bariatric Surgery. A Prospective Study. *Obesity Surgery* 2016;26:1075-80.
67. Coblijn UK, Kuiken SD, Van Wagensveld BA. Comment on: Is esophagogastroduodenoscopy before Roux-en-Y gastric bypass or sleeve gastrectomy mandatory? *Surgery for Obesity and Related Diseases* 2015;11:1192-3.
68. Csendes A, Burgos AM, Smok G, Beltran M. Endoscopic and histologic findings of the foregut in 426 patients with morbid obesity. *Obesity surgery : the official journal of the American Society for Bariatric Surgery and of the Obesity Surgery Society of Australia and New Zealand* 2007;17:28-34.
69. Endo Y, Ohta M, Tada K, *et al.* Clinical significance of upper gastrointestinal endoscopy before laparoscopic bariatric procedures in Japanese patients. *Surgery Today* 2019;49:27-31.
70. Estevez-Fernandez S, Sanchez-Santos R, Marino-Padin E, Gonzalez-Fernandez S, Turnes-Vazquez J. Esophagogastric pathology in morbid obese patient: Preoperative diagnosis and influence in the selection of surgical technique. *Revista Espanola de Enfermedades Digestivas* 2015;107:408-12.
71. Fernandes SR, Meireles LC, Carrilho-Ribeiro L, Velosa J. The Role of Routine Upper Gastrointestinal Endoscopy Before Bariatric Surgery. *Obesity Surgery* 2016;26:2105-10.
72. Heimgartner B, Herzig M, Borbely Y, Kroll D, Nett P, Tutuian R. Symptoms, endoscopic findings and reflux monitoring results in candidates for bariatric surgery. *Digestive and Liver Disease* 2017;49:750-6.

73. Kavanagh R, Smith J, Bashir U, Jones D, Avgenakis E, Nau P. Optimizing bariatric surgery outcomes: a novel preoperative protocol in a bariatric population with gastroesophageal reflux disease. *Surgical Endoscopy* 2019.
74. Masci E, Viaggi P, Mangiavillano B, et al. No increase in prevalence of Barrett's oesophagus in a surgical series of obese patients referred for laparoscopic gastric banding. *Dig Liver Dis* 2011;43:613-5.
75. Munoz R, Ibanez L, Salinas J, et al. Importance of routine preoperative upper GI endoscopy: Why all patients should be evaluated? *Obesity Surgery* 2009;19:427-31.
76. Santo MA, Quintanilha SR, Mietti CA, Kawamoto FM, Marson AG, de Cleva R. Endoscopic Changes Related to Gastroesophageal Reflux Disease: Comparative Study among Bariatric Surgery Patients. *Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery* 2015;28:36-8.
77. Schlottmann F, Sadava EE, Reino R, Galvarini M, Buxhoeveden R. Preoperative endoscopy in bariatric patients may change surgical strategy. *Acta Gastroenterologica Latinoamericana* 2017;47:117-21.
78. Suter M. Comment on: Evaluation of gastroesophageal reflux before and after laparoscopic sleeve gastrectomy using symptom scoring, scintigraphy and endoscopy. *Surgery for Obesity and Related Diseases* 2014;10:605-6.
79. Braghetto I, Csendes A. Prevalence of Barrett's Esophagus in Bariatric Patients Undergoing Sleeve Gastrectomy. *Obesity Surgery* 2016;26:710-4.
80. Csendes A, Orellana O, Martinez G, Burgos AM, Figueroa M, Lanzarini E. Clinical, Endoscopic, and Histologic Findings at the Distal Esophagus and Stomach Before and Late (10.5 Years) After Laparoscopic Sleeve Gastrectomy: Results of a Prospective Study with 93% Follow-Up. *Obesity Surgery* 2019;29:3809-17.
81. Felsenreich DM, Kefurt R, Schermann M, et al. Reflux, Sleeve Dilation, and Barrett's Esophagus after Laparoscopic Sleeve Gastrectomy: Long-Term Follow-Up. *Obesity Surgery* 2017;27:3092-101.
82. Felsenreich DM, Ladinig LM, Beckerhinn P, et al. Update: 10 Years of Sleeve Gastrectomy-the First 103 Patients. *Obesity Surgery* 2018;28:3586-94.
83. Sebastianelli L, Benois M, Vanbiervliet G, et al. Systematic Endoscopy 5 Years After Sleeve Gastrectomy Results in a High Rate of Barrett's Esophagus: Results of a Multicenter Study. *Obesity Surgery* 2019;29:1462-9.
84. Andrew B, Alley JB, Aguilar CE, Fanelli RD. Barrett's esophagus before and after Roux-en-Y gastric bypass for severe obesity. *Surgical Endoscopy* 2018;32:930-6.
85. Braghetto I, Korn O, Csendes A, Gutierrez L, Valladares H, Chacon M. Laparoscopic treatment of obese patients with gastroesophageal reflux disease and Barrett's esophagus: A prospective study. *Obesity Surgery* 2012;22:764-72.
86. Gorodner V, Buxhoeveden R, Clemente G, Sanchez C, Caro L, Grigaites A. Barrett's esophagus after Roux-en-Y gastric bypass: does regression occur? *Surgical Endoscopy* 2017;31:1849-54.

87. Houghton SG, Romero Y, Sarr MG. Effect of Roux-en-Y gastric bypass in obese patients with Barrett's esophagus: attempts to eliminate duodenogastric reflux. *Surgery for Obesity and Related Diseases* 2008;4:1-4.

Table 1. Current published guidelines on use of endoscopy before bariatric surgery

Guideline	Year	Recommendation	Selective or routine
The American Association of Clinical Endocrinologists, the Obesity Society, and the American Society for Metabolic and Bariatric Surgery (AACE/TOS/ASMBS) ³¹	2013	Clinically significant GI symptoms should be evaluated before bariatric surgery with imaging studies, UGI series, or endoscopy (Grade D recommendation)	Selective
The European Association for Endoscopic Surgery (EAES) ³⁰	2005	Upper GI endoscopy or upper GI series is advisable for all bariatric procedures (Grade C recommendation), but is strongly recommended for gastric bypass patients (Grade B recommendation)	Routine
The American Society for Gastrointestinal Endoscopy (ASGE) ³²	2015	The decision to perform preoperative endoscopy should be individualized in patients scheduled to undergo bariatric surgery after a thorough discussion with the surgeon, taking into consideration the type of bariatric procedure performed (low-quality evidence) Patients with symptoms of GERD, such as heartburn, regurgitation, dysphagia, or any postprandial symptoms that suggest a foregut pathology and/or who chronically use antisecretory medications should have a UGI endoscopic evaluation before bariatric surgery.	Selective

Abbreviations: GI, gastrointestinal; UGI, upper gastrointestinal.

Table 2. Studies examining preoperative screening endoscopy for Barrett's esophagus in bariatric surgical patients

Study	Type	N	N demographics	Population included	Prevalence of BE	Normal	Clinical impact	Recommendation for endoscopy
Abou Hussein ⁴²	Retrospective	1278	61% female, BMI = 43.7 ± 8	All bariatric	3.0%	10.6%		Routine
Azagury, ³⁹	Retrospective	319		Asymptomatic bariatric	0.31%	54%	4%	Selective
Bradley, 2015 ⁶⁵	Retrospective	79	76% female, median BMI = 44.6	All bariatric with reflux, dysphagia, or hiatal hernia	16.4%	-	19%	Selective
Carabotti ⁶⁶	Prospective	142	82% female, median BMI = 44	All bariatric	0	53%	3.5%	Routine
Coblijn ⁶⁷	Prospective	523	76.5% female, mean BMI = 46.5	Primary bariatric	1%	49%	62%	Not recommended
Csendes ⁶⁸	Prospective	426	78% female	All bariatric	5.8%	45%	-	Routine
D'Hondt ⁴³	Retrospective	652	Age 39.5 ± 11.3, 70.9% female, BMI = 42.8 ± 5.0	Consecutive RYGB	0.8%	31.9%	7.8%	Routine
D'Silva ⁴¹	Prospective	675	Age 45 ± 9.1, BMI = 43.9 ± 6.9	All bariatric	1.8%	78.5%	9.9%	Routine
Endo ⁶⁹	Retrospective	155	59% female, BMI 45 ± 8	All bariatric	0.6%	34%	10%	Routine
Estevez-Fernandez ⁷⁰	Retrospective	331	82% female, mean BMI = 47.5	All bariatric	0.6%	-	52.6%	Routine
Fernandes ⁷¹	Retrospective	613	78% female, mean = BMI 44.7	All bariatric (selective endoscopy)	0.5%	43.7%	-	-
Heimgartner ⁷²	Prospective	100	68% female, mean BMI = 44.9 ± 6.9	All bariatric	6%	29%	-	Routine
Humphreys ⁴⁰	Retrospective	371		LAGB (selective endoscopy)	0.8%	56%	-	Routine
Kavanagh ⁷³	Retrospective	133	68% female, mean BMI = 46.8	All symptomatic bariatric	8%	-	69.9%	Selective
Masci ⁷⁴	Prospective	1049	78% female, mean BMI = 45.1 ± 4.6	LAGB (selective endoscopy)	0	91.8%	2.3%	-
Mong ³⁴	Retrospective	272	87% female, BMI = 48 ± 7.95	All bariatric (selective endoscopy)	3.7%	88%	0.3%	Routine
Moulla ⁴⁴	Retrospective	636	BMI = 49 (range 31–92)	All bariatric (selective endoscopy)	15.0%	-	1.6%	Selective
Munoz ⁷⁵	Retrospective	626	72% female, BMI 42 ± 6.5	RYGB (selective endoscopy)	0.16%	54%	> 45%	Routine
Ozeki ⁴⁵	Retrospective	260	Age 54.0 ± 9.0, 25% female, BMI = 44.9 ± 7.0	All Veterans undergoing RYGB or SG (routine)	7.4%	33%	-	Selective
Parikh ⁴⁹	Meta-analysis	6616	Mean BMI = 47 ± 3.2	Review of 28 studies on preoperative endoscopy	0.1%	92.4%	7.6%	Selective
Saarinén ⁷⁶	Retrospective	1275	Age 48.5 ± 9.1, 72.6% female, BMI = 46.1 ± 7.0	All bariatric (selective endoscopy)	3.7% (2.2% asymptomatic)	50.7%	24.6%	Routine
Santo ⁷⁶	Retrospective	717		All bariatric	0.28%	-	-	-

				(selective endoscopy)				
Schigt ³⁷	Prospective	523	Age 44.3, 76.7% female, BMI = 46.6	All bariatric (routine endoscopy)	1.3%	49.1%	-	Selective
Schlottmann ⁷⁷	Retrospective	193	64% female, mean = BMI 44.5	All bariatric (selective endoscopy)	1.6%	64%	-	Routine
Schneider ⁴⁶	Retrospective	1190		All bariatric (selective endoscopy)	0.4%	39.5%	2.4%	Routine
Sharaf ⁴⁷	Retrospective	195	Age 41.2, 78.5% female, BMI = 48.9	All bariatric (selective endoscopy)	3.1%	10.3%	61.5%	Routine
Soricelli ⁶⁴	Prospective	144	Mean BMI = 46.2 ± 7.2	SG (routine endoscopy)	13%	-	-	Consider wider screening
Suter ⁷⁸	Prospective	345	80% female, mean BMI = 44.7	Patients being evaluated for bariatric surgery	1.2%	-	-	-
Wolter ⁴⁸	Retrospective	801	Age 43.8 ± 11.4, BMI = 50.1 ± 12.7	All bariatric (routine endoscopy)	2.1%	34.3%	-	Routine
Zeni ³³	Retrospective	169	82% female, mean BMI = 49.7	All bariatric	1.3%	33.3%	9.4%	Routine

Abbreviations: BMI, body mass index; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; LAGB, laparoscopic adjustable gastric band

Table 3. Systematic reviews on bariatric procedures and their impact on BE

Systematic review	Aims	Study details	Results	Conclusions
Adil, 2019 ⁵²	Effect on RYGB on BE with pre- and postendoscopy and biopsy	Eight studies 10,779 patients 117 patients with BE with follow-up >1 year	Regression of BE after RYGB (risk difference -0.56 (95% CI: -0.69 to -0.43), $P < 0.001$): - Short-segment BE (-0.51 (95% CI: -0.68 to -0.33), $P < 0.001$) - Long-segment BE (-0.46 (95% CI: -0.71 to -0.21), $P < 0.001$) Strongly associated with regression of BE versus progression (OR = 31.2 (95% CI: 11.37 to 85.63), $P < 0.001$) Improvement in GERD (-0.93 (95% CI: -1.04 to -0.81), $P < 0.001$)	RYGB improves BE significantly at a >1-year follow-up
Yeung, 2020 ²⁵	Effect of SG on GERD, esophagitis, and BE to clarify long-term clinical sequelae	46 studies (all GERD related pathology) 10,718 patients Five studies with BE with long-term results	The long-term prevalence of BE was 8%. High heterogeneity ($I^2 = 94.1\%$) Increase in postoperative GERD after the sleeve was 19% <i>De novo</i> reflux was 23% The long-term prevalence of esophagitis was 28% 4% required conversion to RYGB for severe reflux Symptoms do not always correlate with pathology	Prevalence of BE following SG is significant Surgical decision making and consent should consider these long-term complications

Table 4. Studies examining effect of SG on incidence of BE

Ref.	N	Population	Follow-up	BE	Results
Braghetto, 2016 (prospective) ⁷⁹	231	Patients with normal preoperative endoscopy 72.7% female, BMI = 38.5 ± 3.1	5–6 years	1.2% <i>de novo</i>	Postoperatively: • BE in 3 (1.2%) (between 5 and 6) years postoperatively • Reflux symptoms in 57 (23.2%) • Erosive esophagitis in 38 (15.5%)
Csendes, 2019 (prospective) ⁸⁰	104	Consecutive SG without (group 1) and with (group 2) reflux	1.6 years	3.8-4.5% <i>de novo</i>	Group 1: Two developed BE (3.8%), 58.5% developed GERD Group 2: Two developed BE (4.5%), 13.5% had a resolution of GERD
Felsenreich, 2017 (prospective) ⁸¹	43	Patients with primary SG 10 years prior, without reflux or HH preoperative	10+ years	15% <i>de novo</i>	<i>De novo</i> Barrett's in 15%, <i>de novo</i> hiatal hernia in 45%. Six patients converted to RYGB due to reflux (14.0%) over 130 months. Lower GI quality of life and higher reflux symptom index in sleeve patients.
Felsenreich, 2018 (prospective) ⁸²	65	Consecutive SG between January 2003 and December 2006	10+ years	9.2% <i>de novo</i>	44 patients had follow-up gastroscopy, of which six had Barrett's metaplasia
Genco, 2017 (prospective) ⁶³	110	Primary SG between July 2007 and January 2010	58 months	17.2% <i>de novo</i>	Increase in erosive esophagitis, GERD symptoms (68.1% versus 33.6%, $P < 0.001$), and PPI intake (57.2% versus 19.1%, $P < 0.0001$). Endoscopic findings not related to symptoms.
Sebastianelli, 2019 (prospective) ⁸³	90	SG who had undergone surgery at least 5 years before without preoperative BE	78 ± 15 months	18.8% <i>de novo</i>	Increase in GERD symptoms (22% to 76%), erosive esophagitis (10% to 41%), and PPI use (22% to 52%), all $P < 0.05$.

Abbreviations: RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; BE, Barrett's esophagus; GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor; EE, erosive esophagitis

Table 5. Studies examining effect of RYGB on incidence of BE

Ref.	Type of gastric bypass	N	Population	Follow-up	BE	Results
Andrew, 2018 (retrospective) ⁸⁴	RYGB	14	Patients with proven BE who underwent RYGB (September 2011–May 2015).	1 year	42.9% resolution	All short-segment BE. 6/14 (42.9%) complete regression to normal 13/14 (92.8%) complied with PPI for 1 year
Braghetto, 2012 (retrospective) ⁸⁵	Resectional RYGB	21	Patients undergoing antireflux operations (including LRRYGB)	1 year	61.9% regression	Regression in IM in 13 (61.9%) Significant reduction in acid reflux, symptoms and erosive esophagitis
Csendes, 2006 (retrospective) ⁵³	Resectional RYGB	557	August 1999 to October 2004	2 years	SSBE: 57% regression LSBE: 20% regression	Twelve patients with BE (2.1%): seven with SSBE and five with LSBE Postoperative: • Regression of 57% with SSBE • Regression of 20% with LSBE • Reflux esophagitis resolved in all patients

						postoperatively
Felsenreich, 2019 (retrospective) ⁵⁵	Revision RYGB	10	Patients converted to RYGB due to BE after SG	33.4 months	80% resolution	Decrease in a 24-h mean acid exposure (36.8% to 3.8%) and mean DeMeester from 100 to 16.3.
Gorodner, 2017 (retrospective) ⁸⁶	RYGB	11	Bariatric cases with baseline BE	41 ± 31 months	36% resolution	Nine SSBE and two SBE Average length of BE 2.1 ± 1.6 cm preoperatively and 1.2 ± 1.2 cm postoperatively ($P >$ 0.05) Remission in four cases (36%): three SSBE and one LSBE.
Houghton, 2008 (retrospective) ⁸⁷	RYGB	5	Patients with Bx proven LSBE undergoing RYGB, with a >1-year follow-up	34 months	40% resolution 80% decreased length	BE length 6 ± 2cm preoperatively to 2 ± 1 cm postoperatively: - Length had decreased/disappeared in four patients - Complete resolution of BE in two patients - Improvement in degree of dysplasia in three patients
Signorini, 2020 (retrospective) ⁵⁴	RYGB	9	Consecutive patients with RYGB	24 months	SSBE: 75% resolution LSBE: 40% resolution	Preoperative BE: SSBE 45% and LSBE 55%: - SSBE 75% resolved - LSBE 40% resolved - No progression to dysplasia

Abbreviations: RYGB, Roux-en-Y gastric bypass; LRRYGB, laparoscopic resectional Roux-en-Y gastric bypass; BE, Barrett's esophagus; SG, sleeve gastrectomy; SSBE, short-segment Barrett's esophagus; LSBE, long-segment Barrett's esophagus; IM, intestinal metaplasia; PPI, proton pump inhibitor.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Ooi, GJ;Browning, A;Hii, MW;Read, M

Title:

Perioperative screening, management, and surveillance of Barrett's esophagus in bariatric surgical patients

Date:

2020-08-13

Citation:

Ooi, G. J., Browning, A., Hii, M. W. & Read, M. (2020). Perioperative screening, management, and surveillance of Barrett's esophagus in bariatric surgical patients. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1481 (1), pp.224-235. <https://doi.org/10.1111/nyas.14441>.

Persistent Link:

<http://hdl.handle.net/11343/276144>